-$0.06 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter

Analysts forecast that Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) will report ($0.06) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Catalyst Pharmaceuticals’ earnings. The highest EPS estimate is ($0.05) and the lowest is ($0.07). Catalyst Pharmaceuticals posted earnings per share of ($0.05) in the same quarter last year, which suggests a negative year-over-year growth rate of 20%. The business is expected to issue its next quarterly earnings report on Wednesday, March 21st.

On average, analysts expect that Catalyst Pharmaceuticals will report full year earnings of ($0.22) per share for the current financial year, with EPS estimates ranging from ($0.23) to ($0.20). For the next year, analysts expect that the firm will post earnings of ($0.28) per share, with EPS estimates ranging from ($0.45) to ($0.13). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Catalyst Pharmaceuticals.

A number of equities research analysts have weighed in on CPRX shares. Zacks Investment Research lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 10th. Roth Capital set a $5.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, November 1st. Piper Jaffray Companies set a $8.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 1st. Finally, SunTrust Banks set a $5.00 price objective on Catalyst Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $6.25.

Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) traded up $0.07 during midday trading on Wednesday, reaching $3.99. The company’s stock had a trading volume of 713,507 shares, compared to its average volume of 1,610,000. Catalyst Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $4.51. The firm has a market cap of $343.32, a price-to-earnings ratio of -19.00 and a beta of 1.68.

A number of hedge funds and other institutional investors have recently modified their holdings of CPRX. Schwab Charles Investment Management Inc. acquired a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $333,000. Rhumbline Advisers acquired a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $209,000. State of Wisconsin Investment Board acquired a new stake in Catalyst Pharmaceuticals during the 2nd quarter valued at approximately $149,000. Bank of New York Mellon Corp grew its stake in Catalyst Pharmaceuticals by 206.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 211,979 shares of the biopharmaceutical company’s stock valued at $585,000 after purchasing an additional 142,803 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Catalyst Pharmaceuticals by 1,833.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,536,300 shares of the biopharmaceutical company’s stock worth $4,240,000 after acquiring an additional 1,456,830 shares in the last quarter. Hedge funds and other institutional investors own 34.75% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “-$0.06 EPS Expected for Catalyst Pharmaceuticals Inc (CPRX) This Quarter” was originally posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://ledgergazette.com/2018/01/10/0-06-eps-expected-for-catalyst-pharmaceuticals-inc-cprx-this-quarter.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Get a free copy of the Zacks research report on Catalyst Pharmaceuticals (CPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply